

FIRST REGULAR SESSION

# HOUSE BILL NO. 812

## 97TH GENERAL ASSEMBLY

---

INTRODUCED BY REPRESENTATIVE RHOADS.

2016L.011

D. ADAM CRUMBLISS, Chief Clerk

---

### AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to synthetic cannabinoids, with penalty provisions.

---

*Be it enacted by the General Assembly of the state of Missouri, as follows:*

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

(1) Has high potential for abuse; and

(2) Has no accepted medical use in treatment in the United States or lacks accepted safety for use in treatment under medical supervision.

2. Schedule I:

(1) The controlled substances listed in this subsection are included in Schedule I;

(2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

(a) Acetyl-alpha-methylfentanyl;

(b) Acetylmethadol;

(c) Allylprodine;

(d) Alphacetylmethadol;

(e) Alphameprodine;

(f) Alphamethadol;

(g) Alpha-methylfentanyl;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

- 18 (h) Alpha-methylthiofentanyl;
- 19 (i) Benzethidine;
- 20 (j) Betacetylmethadol;
- 21 (k) Beta-hydroxyfentanyl;
- 22 (l) Beta-hydroxy-3-methylfentanyl;
- 23 (m) Betameprodine;
- 24 (n) Betamethadol;
- 25 (o) Betaprodine;
- 26 (p) Clonitazene;
- 27 (q) Dextromoramide;
- 28 (r) Diampromide;
- 29 (s) Diethylthiambutene;
- 30 (t) Difenoxin;
- 31 (u) Dimenoxadol;
- 32 (v) Dimepheptanol;
- 33 (w) Dimethylthiambutene;
- 34 (x) Dioxaphetyl butyrate;
- 35 (y) Dipipanone;
- 36 (z) Ethylmethylthiambutene;
- 37 (aa) Etonitazene;
- 38 (bb) Etixeridine;
- 39 (cc) Furethidine;
- 40 (dd) Hydroxypethidine;
- 41 (ee) Ketobemidone;
- 42 (ff) Levomoramide;
- 43 (gg) Levophenacymorphan;
- 44 (hh) 3-Methylfentanyl;
- 45 (ii) 3-Methylthiofentanyl;
- 46 (jj) Morpheridine;
- 47 (kk) MPPP;
- 48 (ll) Noracymethadol;
- 49 (mm) Norlevorphanol;
- 50 (nn) Normethadone;
- 51 (oo) Norpipanone;
- 52 (pp) Para-fluorofentanyl;
- 53 (qq) PEPAP;

- 54 (rr) Phenadoxone;
- 55 (ss) Phenampromide;
- 56 (tt) Phenomorphan;
- 57 (uu) Phenoperidine;
- 58 (vv) Piritramide;
- 59 (ww) Proheptazine;
- 60 (xx) Properidine;
- 61 (yy) Propiram;
- 62 (zz) Racemoramide;
- 63 (aaa) Thiofentanyl;
- 64 (bbb) Tilidine;
- 65 (ccc) Trimeperidine;

66 (3) Any of the following opium derivatives, their salts, isomers and salts of isomers  
67 unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers  
68 is possible within the specific chemical designation:

- 69 (a) Acetorphine;
- 70 (b) Acetyldihydrocodeine;
- 71 (c) Benzylmorphine;
- 72 (d) Codeine methylbromide;
- 73 (e) Codeine-N-Oxide;
- 74 (f) Cyprenorphine;
- 75 (g) Desomorphine;
- 76 (h) Dihydromorphine;
- 77 (i) Drotebanol;
- 78 (j) Etorphine (except hydrochloride salt);
- 79 (k) Heroin;
- 80 (l) Hydromorphenol;
- 81 (m) Methyldesorphine;
- 82 (n) Methyldihydromorphine;
- 83 (o) Morphine methylbromide;
- 84 (p) Morphine methylsulfonate;
- 85 (q) Morphine-N-Oxide;
- 86 (r) Myrophine;
- 87 (s) Nicocodeine;
- 88 (t) Nicomorphine;
- 89 (u) Normorphine;

- 90 (v) Pholcodine;
- 91 (w) Thebacon;
- 92 (4) Any material, compound, mixture or preparation which contains any quantity of the
- 93 following hallucinogenic substances, their salts, isomers and salts of isomers, unless specifically
- 94 excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within
- 95 the specific chemical designation:
- 96 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 97 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 98 (c) 2,5-dimethoxyamphetamine;
- 99 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 100 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 101 (f) 4-methoxyamphetamine;
- 102 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 103 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 104 (i) 3,4-methylenedioxyamphetamine;
- 105 (j) 3,4-methylenedioxymethamphetamine;
- 106 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 107 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 108 (m) 3,4,5-trimethoxyamphetamine;
- 109 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts, and salts of
- 110 isomers;
- 111 (o) Alpha-ethyltryptamine;
- 112 (p) Alpha-methyltryptamine;
- 113 (q) Bufotenine;
- 114 (r) Diethyltryptamine;
- 115 (s) Dimethyltryptamine;
- 116 (t) 5-methoxy-N,N-diisopropyltryptamine;
- 117 (u) Ibogaine;
- 118 (v) Lysergic acid diethylamide;
- 119 (w) Marijuana or marihuana;
- 120 (x) Mescaline;
- 121 (y) Parahexyl;
- 122 (z) Peyote, to include all parts of the plant presently classified botanically as Lophophora
- 123 Williamsil Lemaire, whether growing or not; the seeds thereof; any extract from any part of such
- 124 plant; and every compound, manufacture, salt, derivative, mixture or preparation of the plant,
- 125 its seed or extracts;

- 126 (aa) N-ethyl-3-piperidyl benzilate;  
127 (bb) N-methyl-3-piperidyl benzilate;  
128 (cc) Psilocybin;  
129 (dd) Psilocyn;  
130 (ee) Tetrahydrocannabinols naturally contained in a plant of the genus Cannabis  
131 (cannabis plant), as well as synthetic equivalents of the substances contained in the cannabis  
132 plant, or in the resinous extractives of such plant, or synthetic substances, derivatives, and their  
133 isomers with similar chemical structure and pharmacological activity to those substances  
134 contained in the plant, such as the following:
- 135 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;  
136 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;  
137 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;  
138 d. Any compounds of these structures, regardless of numerical designation of atomic  
139 positions covered;
- 140 (ff) Ethylamine analog of phencyclidine;  
141 (gg) Pyrrolidine analog of phencyclidine;  
142 (hh) Thiophene analog of phencyclidine;  
143 (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;  
144 (jj) Salvia divinorum;  
145 (kk) Salvinorin A;  
146 (ll) Synthetic cannabinoids:
- 147 a. Any compound structurally derived from 3-(1-naphthoyl)indole or  
148 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by  
149 alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl  
150 [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-**  
151 **morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether or not further  
152 substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any  
153 extent. Including, but not limited to:
- 154 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;  
155 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;  
156 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;  
157 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;  
158 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;  
159 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;  
160 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;  
161 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;

- 162 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;  
163 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;  
164 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;  
165 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;  
166 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the  
167 nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
168 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)**  
169 **methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether  
170 or not further substituted in the pyrrole ring to any extent, whether or not substituted in the  
171 naphthyl ring to any extent;  
172 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene by substitution  
173 at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
174 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**  
175 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**  
176 group, whether or not further substituted in the indene ring to any extent, whether or not  
177 substituted in the naphthyl ring to any extent;  
178 d. Any compound structurally derived from 3-phenylacetylindole by substitution at the  
179 nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,  
180 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)**  
181 **methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether  
182 or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl  
183 ring to any extent. Including, but not limited to:  
184 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;  
185 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;  
186 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;  
187 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;  
188 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;  
189 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by  
190 substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
191 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-**  
192 **pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl**  
193 group, whether or not substituted in the cyclohexyl ring to any extent. Including, but not limited  
194 to:  
195 (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-  
196 yl)phenol), where side chain n=5, and homologues where side chain n=4,6, or 7;

f. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl [or] , 2-(4-morpholinyl)ethyl, **1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl** group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Including, but not limited to:

(i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;

(ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;

g. Any compound structurally derived from **1H-indol-3-yl-(2,2,3,3-tetramethylcyclopropyl)-methanone** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent. Including, but not limited to:

(i) UR-144, or (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone;

(ii) **XLR-11, or (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone;**

h. Any compound structurally derived from **3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl group to any extent. Including, but not limited to:

(i) AM-1248, or 1-(N-methyl-2-piperidinyl)methyl-3-(1-adamantoyl)indole;

(ii) AB-001, or 1-pentyl-3-(1-adamantoyl)indole;

i. Any compound structurally derived from **N-adamantyl-1H-indole-3-carboxamide** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl group to any extent. Including, but not limited to **2NE1, or 1-pentyl-N-adamantyl-1H-indole-3-carboxamide;**

j. Any compound structurally derived from the **N-adamantyl-1H-indazole-3-carboxamide** by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-

233 **morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent,**  
234 **whether or not substituted in the adamantyl group to any extent. Including, but not**  
235 **limited to AKB48, or 1-pentyl-N-adamantyl-1H-indazole-3-carboxamide;**

236 **k.** CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-  
237 yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

238 **[h.] l.** HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-  
239 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

240 **[i.] m.** HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-  
241 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;

242 **[j.]** CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-  
243 yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;

244 **k.] n.** Dimethylheptylpyran, or DMHP;

245 (5) Any material, compound, mixture or preparation containing any quantity of the  
246 following substances having a depressant effect on the central nervous system, including their  
247 salts, isomers and salts of isomers whenever the existence of these salts, isomers and salts of  
248 isomers is possible within the specific chemical designation:

249 (a) Gamma-hydroxybutyric acid;

250 (b) Mecloqualone;

251 (c) Methaqualone;

252 (6) Any material, compound, mixture or preparation containing any quantity of the  
253 following substances having a stimulant effect on the central nervous system, including their  
254 salts, isomers and salts of isomers:

255 (a) Aminorex;

256 (b) N-benzylpiperazine;

257 (c) Cathinone;

258 (d) Fenethylamine;

259 (e) 3-Fluoromethcathinone;

260 (f) 4-Fluoromethcathinone;

261 (g) Mephedrone, or 4-methylmethcathinone;

262 (h) Methcathinone;

263 (i) 4-methoxymethcathinone;

264 (j) (+,-)cis-4-methylaminorex ((+,-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazoline);

265 (k) Methylenedioxypyrovalerone, MDPV, or (1-(1,3-Benzodioxol-5-yl)-2-(1-  
266 pyrrolidinyl)-1-pentanone;

267 (l) Methylone, or 3,4-Methylenedioxymethcathinone;

268 (m) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP;



269 (n) N-ethylamphetamine;  
270 (o) N,N-dimethylamphetamine;  
271 (7) A temporary listing of substances subject to emergency scheduling under federal law  
272 shall include any material, compound, mixture or preparation which contains any quantity of the  
273 following substances:  
274 (a) N-(1-benzyl-4-piperidyl)-N phenylpropanamide (benzylfentanyl), its optical isomers,  
275 salts and salts of isomers;  
276 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide (thenylfentanyl), its  
277 optical isomers, salts and salts of isomers;  
278 (8) Khat, to include all parts of the plant presently classified botanically as *catha edulis*,  
279 whether growing or not; the seeds thereof; any extract from any part of such plant; and every  
280 compound, manufacture, salt, derivative, mixture, or preparation of the plant, its seed or extracts.  
281 3. The department of health and senior services shall place a substance in Schedule II  
282 if it finds that:  
283 (1) The substance has high potential for abuse;  
284 (2) The substance has currently accepted medical use in treatment in the United States,  
285 or currently accepted medical use with severe restrictions; and  
286 (3) The abuse of the substance may lead to severe psychic or physical dependence.  
287 4. The controlled substances listed in this subsection are included in Schedule II:  
288 (1) Any of the following substances whether produced directly or indirectly by extraction  
289 from substances of vegetable origin, or independently by means of chemical synthesis, or by  
290 combination of extraction and chemical synthesis:  
291 (a) Opium and opiate and any salt, compound, derivative or preparation of opium or  
292 opiate, excluding apomorphine, thebaine-derived butorphanol, dextrophan, nalbuphine,  
293 nalmefene, naloxone and naltrexone, and their respective salts but including the following:  
294 a. Raw opium;  
295 b. Opium extracts;  
296 c. Opium fluid;  
297 d. Powdered opium;  
298 e. Granulated opium;  
299 f. Tincture of opium;  
300 g. Codeine;  
301 h. Ethylmorphine;  
302 i. Etorphine hydrochloride;  
303 j. Hydrocodone;  
304 k. Hydromorphone;

- 305 l. Metopon;
- 306 m. Morphine;
- 307 n. Oxycodone;
- 308 o. Oxymorphone;
- 309 p. Thebaine;
- 310 (b) Any salt, compound, derivative, or preparation thereof which is chemically
- 311 equivalent or identical with any of the substances referred to in this subdivision, but not
- 312 including the isoquinoline alkaloids of opium;
- 313 (c) Opium poppy and poppy straw;
- 314 (d) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
- 315 any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical
- 316 with any of these substances, but not including decocainized coca leaves or extractions which
- 317 do not contain cocaine or ecgonine;
- 318 (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid
- 319 or powder form which contains the phenanthrene alkaloids of the opium poppy);
- 320 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts
- 321 of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within
- 322 the specific chemical designation, dextrorphan and levopropoxyphene excepted:
- 323 (a) Alfentanil;
- 324 (b) Alphaprodine;
- 325 (c) Anileridine;
- 326 (d) Bezitramide;
- 327 (e) Bulk dextropropoxyphene;
- 328 (f) Carfentanil;
- 329 (g) Dihydrocodeine;
- 330 (h) Diphenoxylate;
- 331 (i) Fentanyl;
- 332 (j) Isomethadone;
- 333 (k) Levo-alphacetylmethadol;
- 334 (l) Levomethorphan;
- 335 (m) Levorphanol;
- 336 (n) Metazocine;
- 337 (o) Methadone;
- 338 (p) Meperidine;
- 339 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane;

- 340 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane--carboxylic  
341 acid;
- 342 (s) Pethidine (meperidine);
- 343 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 344 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 345 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 346 (w) Phenazocine;
- 347 (x) Piminodine;
- 348 (y) Racemethorphan;
- 349 (z) Racemorphan;
- 350 (aa) Remifentanyl;
- 351 (bb) Sufentanyl;
- 352 (cc) Tapentadol;
- 353 (3) Any material, compound, mixture, or preparation which contains any quantity of the  
354 following substances having a stimulant effect on the central nervous system:
- 355 (a) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 356 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;
- 357 (c) Methamphetamine, its salts, isomers, and salts of its isomers;
- 358 (d) Phenmetrazine and its salts;
- 359 (e) Methylphenidate;
- 360 (4) Any material, compound, mixture, or preparation which contains any quantity of the  
361 following substances having a depressant effect on the central nervous system, including its salts,  
362 isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers  
363 is possible within the specific chemical designation:
- 364 (a) Amobarbital;
- 365 (b) Glutethimide;
- 366 (c) Pentobarbital;
- 367 (d) Phencyclidine;
- 368 (e) Secobarbital;
- 369 (5) Any material or compound which contains any quantity of nabilone;
- 370 (6) Any material, compound, mixture, or preparation which contains any quantity of the  
371 following substances:
- 372 (a) Immediate precursor to amphetamine and methamphetamine: Phenylacetone;
- 373 (b) Immediate precursors to phencyclidine (PCP):
- 374 a. 1-phenylcyclohexylamine;
- 375 b. 1-piperidinocyclohexanecarbonitrile (PCC);

376 (7) Any material, compound, mixture, or preparation which contains any quantity of the  
377 following alkyl nitrites:

378 (a) Amyl nitrite;

379 (b) Butyl nitrite.

380 5. The department of health and senior services shall place a substance in Schedule III  
381 if it finds that:

382 (1) The substance has a potential for abuse less than the substances listed in Schedules  
383 I and II;

384 (2) The substance has currently accepted medical use in treatment in the United States;  
385 and

386 (3) Abuse of the substance may lead to moderate or low physical dependence or high  
387 psychological dependence.

388 6. The controlled substances listed in this subsection are included in Schedule III:

389 (1) Any material, compound, mixture, or preparation which contains any quantity of the  
390 following substances having a potential for abuse associated with a stimulant effect on the  
391 central nervous system:

392 (a) Benzphetamine;

393 (b) Chlorphentermine;

394 (c) Clortermine;

395 (d) Phendimetrazine;

396 (2) Any material, compound, mixture or preparation which contains any quantity or salt  
397 of the following substances or salts having a depressant effect on the central nervous system:

398 (a) Any material, compound, mixture or preparation which contains any quantity or salt  
399 of the following substances combined with one or more active medicinal ingredients:

400 a. Amobarbital;

401 b. Secobarbital;

402 c. Pentobarbital;

403 (b) Any suppository dosage form containing any quantity or salt of the following:

404 a. Amobarbital;

405 b. Secobarbital;

406 c. Pentobarbital;

407 (c) Any substance which contains any quantity of a derivative of barbituric acid or its  
408 salt;

409 (d) Chlorhexadol;

410 (e) Embutramide;

411 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of isomers contained in  
412 a drug product for which an application has been approved under Section 505 of the federal  
413 Food, Drug, and Cosmetic Act;

414 (g) Ketamine, its salts, isomers, and salts of isomers;

415 (h) Lysergic acid;

416 (i) Lysergic acid amide;

417 (j) Methyprylon;

418 (k) Sulfondiethylmethane;

419 (l) Sulfonethylmethane;

420 (m) Sulfonmethane;

421 (n) Tiletamine and zolazepam or any salt thereof;

422 (3) Nalorphine;

423 (4) Any material, compound, mixture, or preparation containing limited quantities of any  
424 of the following narcotic drugs or their salts:

425 (a) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
426 ninety milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid  
427 of opium;

428 (b) Not more than 1.8 grams of codeine per one hundred milliliters or not more than  
429 ninety milligrams per dosage unit with one or more active, nonnarcotic ingredients in recognized  
430 therapeutic amounts;

431 (c) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
432 or not more than fifteen milligrams per dosage unit, with a fourfold or greater quantity of an  
433 isoquinoline alkaloid of opium;

434 (d) Not more than three hundred milligrams of hydrocodone per one hundred milliliters  
435 or not more than fifteen milligrams per dosage unit, with one or more active nonnarcotic  
436 ingredients in recognized therapeutic amounts;

437 (e) Not more than 1.8 grams of dihydrocodeine per one hundred milliliters or not more  
438 than ninety milligrams per dosage unit, with one or more active nonnarcotic ingredients in  
439 recognized therapeutic amounts;

440 (f) Not more than three hundred milligrams of ethylmorphine per one hundred milliliters  
441 or not more than fifteen milligrams per dosage unit, with one or more active, nonnarcotic  
442 ingredients in recognized therapeutic amounts;

443 (g) Not more than five hundred milligrams of opium per one hundred milliliters or per  
444 one hundred grams or not more than twenty-five milligrams per dosage unit, with one or more  
445 active nonnarcotic ingredients in recognized therapeutic amounts;

(h) Not more than fifty milligrams of morphine per one hundred milliliters or per one hundred grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;

(5) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth in subdivision (6) of this subsection; buprenorphine;

(6) Anabolic steroids. Any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that promotes muscle growth, except an anabolic steroid which is expressly intended for administration through implants to cattle or other nonhuman species and which has been approved by the Secretary of Health and Human Services for that administration. If any person prescribes, dispenses, or distributes such steroid for human use, such person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of this subdivision. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any quantity of the following substances, including its salts, esters and ethers:

- (a)  $3\beta,17$ -dihydroxy-5 $\alpha$ -androstane;
- (b)  $3\alpha,17\beta$ -dihydroxy-5 $\alpha$ -androstane;
- (c) 5 $\alpha$ -androstan-3,17-dione;
- (d) 1-androstenediol ( $3\beta,17\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene);
- (e) 1-androstenediol ( $3\alpha,17\beta$ -dihydroxy-5 $\alpha$ -androst-1-ene);
- (f) 4-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-4-ene);
- (g) 5-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-5-ene);
- (h) 1-androstenedione ([5 $\alpha$ ]-androst-1-en-3,17-dione);
- (i) 4-androstenedione (androst-4-en-3,17-dione);
- (j) 5-androstenedione (androst-5-en-3,17-dione);
- (k) Bolasterone (7 $\alpha$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- (l) Boldenone (17 $\beta$ -hydroxyandrost-1,4,-diene-3-one);
- (m) Boldione;
- (n) Calusterone (7 $\beta$ , 17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- (o) Clostebol (4-chloro-17 $\beta$ -hydroxyandrost-4-en-3-one);
- (p) Dehydrochloromethyltestosterone (4-chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-androst-1,4-dien-3-one);
- (q) Desoxymethyltestosterone;
- (r)  $\Delta 1$ -dihydrotestosterone (a.k.a. '1-testosterone')(17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);
- (s) 4-dihydrotestosterone (17 $\beta$ -hydroxy-androstan-3-one);
- (t) Drostanolone (17 $\beta$ -hydroxy-2 $\alpha$ -methyl-5 $\alpha$ -androstan-3-one);

- 482 (u) Ethylestrenol (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-ene);
- 483 (v) Fluoxymesterone (9-fluoro-17 $\alpha$ -methyl-11 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-en-3-one);
- 484 (w) Formebolone (2-formyl-17 $\alpha$ -methyl-11 $\alpha$ ,17 $\beta$ -dihydroxyandrost-1,4-dien-3-one);
- 485 (x) Furazabol (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrostano[2,3-c]-furazan);
- 486 (y) 13 $\beta$ -ethyl-17 $\beta$ -hydroxygon-4-en-3-one;
- 487 (z) 4-hydroxytestosterone (4,17 $\beta$ -dihydroxy-androst-4-en-3-one);
- 488 (aa) 4-hydroxy-19-nortestosterone (4,17 $\beta$ -dihydroxy-estr-4-en-3-one);
- 489 (bb) Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5-androstan-3-one);
- 490 (cc) Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-one);
- 491 (dd) Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-dien-3-one);
- 492 (ee) Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-ene);
- 493 (ff) Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one);
- 494 (gg) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane);
- 495 (hh) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane);
- 496 (ii) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene;
- 497 (jj) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-hydroxy-17 $\beta$ -hydroxyestr-4-en-3-  
498 one);
- 499 (kk) Methyldienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9(10)-dien-3-one);
- 500 (ll) Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-4,9-11-trien-3-one);
- 501 (mm) Methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-4-en-3-one);
- 502 (nn) Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- 503 (oo) 17 $\alpha$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-  
504 one) (a.k.a. '17- $\alpha$ -methyl-1-testosterone');
- 505 (pp) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);
- 506 (qq) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-ene);
- 507 (rr) 19-nor-4-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-4-ene);
- 508 (ss) 19-nor-4,9(10)-androstadienedione;
- 509 (tt) 19-nor-5-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-5-ene);
- 510 (uu) 19-nor-5-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxyestr-5-ene);
- 511 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 512 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 513 (xx) Norbolethone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4-en-3-one);
- 514 (yy) Norclostebol (4-chloro-17 $\beta$ -hydroxyestr-4-en-3-one);
- 515 (zz) Norethandrolone (17 $\alpha$ -ethyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- 516 (aaa) Normethandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestr-4-en-3-one);
- 517 (bbb) Oxandrolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-androstan-3-one);

518 (ccc) Oxymesterone (17 $\alpha$ -methyl-4,17 $\beta$ -dihydroxyandrost-4-en-3-one);  
519 (ddd) Oxymethalone (17 $\alpha$ -methyl-2-hydroxymethylene-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androstan-3-  
520 one);  
521 (eee) Stanozolol (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-androst-2-eno[3,2-c]-pyrazole);  
522 (fff) Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5 $\alpha$ ]-androst-1-en-3-one);  
523 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrost-1,4-dien-17-oic acid lactone);  
524 (hhh) Testosterone (17 $\beta$ -hydroxyandrost-4-en-3-one);  
525 (iii) Tetrahydrogestrinone (13 $\beta$ ,17 $\alpha$ -diethyl-17 $\beta$ -hydroxygon-4,9,11-trien-3-one);  
526 (jjj) Trenbolone (17 $\beta$ -hydroxyestr-4,9,11-trien-3-one);  
527 (kkk) Any salt, ester, or ether of a drug or substance described or listed in this  
528 subdivision, except an anabolic steroid which is expressly intended for administration through  
529 implants to cattle or other nonhuman species and which has been approved by the Secretary of  
530 Health and Human Services for that administration;  
531 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a  
532 United States Food and Drug Administration approved drug product;  
533 (8) The department of health and senior services may except by rule any compound,  
534 mixture, or preparation containing any stimulant or depressant substance listed in subdivisions  
535 (1) and (2) of this subsection from the application of all or any part of sections 195.010 to  
536 195.320 if the compound, mixture, or preparation contains one or more active medicinal  
537 ingredients not having a stimulant or depressant effect on the central nervous system, and if the  
538 admixtures are included therein in combinations, quantity, proportion, or concentration that  
539 vitiate the potential for abuse of the substances which have a stimulant or depressant effect on  
540 the central nervous system.  
541 7. The department of health and senior services shall place a substance in Schedule IV  
542 if it finds that:  
543 (1) The substance has a low potential for abuse relative to substances in Schedule III;  
544 (2) The substance has currently accepted medical use in treatment in the United States;  
545 and  
546 (3) Abuse of the substance may lead to limited physical dependence or psychological  
547 dependence relative to the substances in Schedule III.  
548 8. The controlled substances listed in this subsection are included in Schedule IV:  
549 (1) Any material, compound, mixture, or preparation containing any of the following  
550 narcotic drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities  
551 as set forth below:  
552 (a) Not more than one milligram of difenoxin and not less than twenty-five micrograms  
553 of atropine sulfate per dosage unit;



554 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-  
555 propionoxybutane);

556 (c) Any of the following limited quantities of narcotic drugs or their salts, which shall  
557 include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer  
558 upon the compound, mixture or preparation valuable medicinal qualities other than those  
559 possessed by the narcotic drug alone:

560 a. Not more than two hundred milligrams of codeine per one hundred milliliters or per  
561 one hundred grams;

562 b. Not more than one hundred milligrams of dihydrocodeine per one hundred milliliters  
563 or per one hundred grams;

564 c. Not more than one hundred milligrams of ethylmorphine per one hundred milliliters  
565 or per one hundred grams;

566 (2) Any material, compound, mixture or preparation containing any quantity of the  
567 following substances, including their salts, isomers, and salts of isomers whenever the existence  
568 of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

569 (a) Alprazolam;

570 (b) Barbitol;

571 (c) Bromazepam;

572 (d) Camazepam;

573 (e) Chloral betaine;

574 (f) Chloral hydrate;

575 (g) Chlordiazepoxide;

576 (h) Clobazam;

577 (i) Clonazepam;

578 (j) Clorazepate;

579 (k) Clotiazepam;

580 (l) Cloxazolam;

581 (m) Delorazepam;

582 (n) Diazepam;

583 (o) Dichloralphenazone;

584 (p) Estazolam;

585 (q) Ethchlorvynol;

586 (r) Ethinamate;

587 (s) Ethyl loflazepate;

588 (t) Fludiazepam;

589 (u) Flunitrazepam;

590 (v) Flurazepam;  
591 (w) Fospropofol;  
592 (x) Halazepam;  
593 (y) Haloxazolam;  
594 (z) Ketazolam;  
595 (aa) Loprazolam;  
596 (bb) Lorazepam;  
597 (cc) Lormetazepam;  
598 (dd) Mebutamate;  
599 (ee) Medazepam;  
600 (ff) Meprobamate;  
601 (gg) Methohexital;  
602 (hh) Methylphenobarbital (mephobarbital);  
603 (ii) Midazolam;  
604 (jj) Nimetazepam;  
605 (kk) Nitrazepam;  
606 (ll) Nordiazepam;  
607 (mm) Oxazepam;  
608 (nn) Oxazolam;  
609 (oo) Paraldehyde;  
610 (pp) Petrichloral;  
611 (qq) Phenobarbital;  
612 (rr) Pinazepam;  
613 (ss) Prazepam;  
614 (tt) Quazepam;  
615 (uu) Temazepam;  
616 (vv) Tetrazepam;  
617 (ww) Triazolam;  
618 (xx) Zaleplon;  
619 (yy) Zolpidem;  
620 (zz) Zopiclone;

621 (3) Any material, compound, mixture, or preparation which contains any quantity of the  
622 following substance including its salts, isomers and salts of isomers whenever the existence of  
623 such salts, isomers and salts of isomers is possible: fenfluramine;

624 (4) Any material, compound, mixture or preparation containing any quantity of the  
625 following substances having a stimulant effect on the central nervous system, including their  
626 salts, isomers and salts of isomers:

- 627 (a) Cathine ((+)-norpseudoephedrine);
- 628 (b) Diethylpropion;
- 629 (c) Fencamfamin;
- 630 (d) Fenproporex;
- 631 (e) Mazindol;
- 632 (f) Mefenorex;
- 633 (g) Modafinil;
- 634 (h) Pemoline, including organometallic complexes and chelates thereof;
- 635 (i) Phentermine;
- 636 (j) Pipradrol;
- 637 (k) Sibutramine;
- 638 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);

639 (5) Any material, compound, mixture or preparation containing any quantity of the  
640 following substance, including its salts:

- 641 (a) butorphanol;
- 642 (b) pentazocine;

643 (6) Ephedrine, its salts, optical isomers and salts of optical isomers, when the substance  
644 is the only active medicinal ingredient;

645 (7) The department of health and senior services may except by rule any compound,  
646 mixture, or preparation containing any depressant substance listed in subdivision (1) of this  
647 subsection from the application of all or any part of sections 195.010 to 195.320 if the  
648 compound, mixture, or preparation contains one or more active medicinal ingredients not having  
649 a depressant effect on the central nervous system, and if the admixtures are included therein in  
650 combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the  
651 substances which have a depressant effect on the central nervous system.

652 9. The department of health and senior services shall place a substance in Schedule V  
653 if it finds that:

654 (1) The substance has low potential for abuse relative to the controlled substances listed  
655 in Schedule IV;

656 (2) The substance has currently accepted medical use in treatment in the United States;  
657 and

658 (3) The substance has limited physical dependence or psychological dependence liability  
659 relative to the controlled substances listed in Schedule IV.

660 10. The controlled substances listed in this subsection are included in Schedule V:

661 (1) Any compound, mixture or preparation containing any of the following narcotic  
662 drugs or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set  
663 forth below, which also contains one or more nonnarcotic active medicinal ingredients in  
664 sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal  
665 qualities other than those possessed by the narcotic drug alone:

666 (a) Not more than two and five-tenths milligrams of diphenoxylate and not less than  
667 twenty-five micrograms of atropine sulfate per dosage unit;

668 (b) Not more than one hundred milligrams of opium per one hundred milliliters or per  
669 one hundred grams;

670 (c) Not more than five-tenths milligram of difenoxin and not less than twenty-five  
671 micrograms of atropine sulfate per dosage unit;

672 (2) Any material, compound, mixture or preparation which contains any quantity of the  
673 following substance having a stimulant effect on the central nervous system including its salts,  
674 isomers and salts of isomers: pyrovalerone;

675 (3) Any compound, mixture, or preparation containing any detectable quantity of  
676 pseudoephedrine or its salts or optical isomers, or salts of optical isomers or any compound,  
677 mixture, or preparation containing any detectable quantity of ephedrine or its salts or optical  
678 isomers, or salts of optical isomers;

679 (4) Unless specifically exempted or excluded or unless listed in another schedule, any  
680 material, compound, mixture, or preparation which contains any quantity of the following  
681 substances having a depressant effect on the central nervous system, including its salts:

682 (a) Lacosamide;

683 (b) Pregabalin.

684 11. If any compound, mixture, or preparation as specified in subdivision (3) of  
685 subsection 10 of this section is dispensed, sold, or distributed in a pharmacy without a  
686 prescription:

687 (1) All packages of any compound, mixture, or preparation containing any detectable  
688 quantity of pseudoephedrine, its salts or optical isomers, or salts of optical isomers or ephedrine,  
689 its salts or optical isomers, or salts of optical isomers, shall be offered for sale only from behind  
690 a pharmacy counter where the public is not permitted, and only by a registered pharmacist or  
691 registered pharmacy technician; and

692 (2) Any person purchasing, receiving or otherwise acquiring any compound, mixture,  
693 or preparation containing any detectable quantity of pseudoephedrine, its salts or optical isomers,  
694 or salts of optical isomers or ephedrine, its salts or optical isomers, or salts of optical isomers  
695 shall be at least eighteen years of age; and

696 (3) The pharmacist, intern pharmacist, or registered pharmacy technician shall require  
697 any person, [prior to their] **before such person's** purchasing, receiving or otherwise acquiring  
698 such compound, mixture, or preparation to furnish suitable photo identification that is issued by  
699 a state or the federal government or a document that, with respect to identification, is considered  
700 acceptable and showing the date of birth of the person;

701 (4) The seller shall deliver the product directly into the custody of the purchaser.

702 12. Pharmacists, intern pharmacists, and registered pharmacy technicians shall  
703 implement and maintain an electronic log of each transaction. Such log shall include the  
704 following information:

705 (1) The name, address, and signature of the purchaser;

706 (2) The amount of the compound, mixture, or preparation purchased;

707 (3) The date and time of each purchase; and

708 (4) The name or initials of the pharmacist, intern pharmacist, or registered pharmacy  
709 technician who dispensed the compound, mixture, or preparation to the purchaser.

710 13. Each pharmacy shall submit information regarding sales of any compound, mixture,  
711 or preparation as specified in subdivision (3) of subsection 10 of this section in accordance with  
712 transmission methods and frequency established by the department by regulation;

713 14. No person shall dispense, sell, purchase, receive, or otherwise acquire quantities  
714 greater than those specified in this chapter.

715 15. All persons who dispense or offer for sale pseudoephedrine and ephedrine products  
716 in a pharmacy shall ensure that all such products are located only behind a pharmacy counter  
717 where the public is not permitted.

718 16. Any person who knowingly or recklessly violates the provisions of subsections 11  
719 to 15 of this section is guilty of a class A misdemeanor.

720 17. The scheduling of substances specified in subdivision (3) of subsection 10 of this  
721 section and subsections 11, 12, 14, and 15 of this section shall not apply to any compounds,  
722 mixtures, or preparations that are in liquid or liquid-filled gel capsule form or to any compound,  
723 mixture, or preparation specified in subdivision (3) of subsection 10 of this section which must  
724 be dispensed, sold, or distributed in a pharmacy pursuant to a prescription.

725 18. The manufacturer of a drug product or another interested party may apply with the  
726 department of health and senior services for an exemption from this section. The department of  
727 health and senior services may grant an exemption by rule from this section if the department  
728 finds the drug product is not used in the illegal manufacture of methamphetamine or other  
729 controlled or dangerous substances. The department of health and senior services shall rely on  
730 reports from law enforcement and law enforcement evidentiary laboratories in determining if the  
731 proposed product can be used to manufacture illicit controlled substances.

732           19. The department of health and senior services shall revise and republish the schedules  
733 annually.

734           20. The department of health and senior services shall promulgate rules under chapter  
735 536 regarding the security and storage of Schedule V controlled substances, as described in  
736 subdivision (3) of subsection 10 of this section, for distributors as registered by the department  
737 of health and senior services.

738           21. Logs of transactions required to be kept and maintained by this section and section  
739 195.417 shall create a rebuttable presumption that the person whose name appears in the logs is  
740 the person whose transactions are recorded in the logs.

✓